Given the overlapping mechanisms of cendakimab and dupilumab targeting IL-13, concern arose while evaluating this patient that cendakimab could similarly be associated with CTCL. Here, IL13 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.